

# Nitrate partially inhibits lipopolysaccharide-induced inflammation by maintaining mitochondrial function

Journal of International Medical Research

48(2) 1–14

© The Author(s) 2020

Article reuse guidelines:

[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)

DOI: 10.1177/0300060520902605

[journals.sagepub.com/home/imr](https://journals.sagepub.com/home/imr)



Yang Yang, Shaoqing Li, Yi Qu, Xue Wang,  
Wei An, Zhilin Li, Zhengxue Han and  
Lizheng Qin 

## Abstract

**Objective:** Nitrate has been reported to protect cells *via* the nitrate-nitrite-nitric oxide (NO) pathway. Most studies tend to use nitrite to investigate the mechanisms of this pathway. However, the latest studies have confirmed that mammals can directly degrade nitrate *via* xanthine oxidoreductase (XOR). The hypothesis is that nitrate could play a protective role in inflammatory responses independent of bacterial nitrate reductases.

**Methods:** Mouse RAW264.7 macrophages were pre-incubated with sodium nitrate (10, 100, and 500  $\mu$ M) for 2 hours, and then treated with lipopolysaccharide (LPS) for 2 hours to induce inflammation. The Quantikine Immunoassay was used to measure interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) concentrations in the supernatant. The fluorescence intensity ratio of red/green from JC-1 was used to assay mitochondrial membrane potential. The fluorescence intensity of MitoSOX Red was used to indicate the generation of mitochondrial reactive oxygen species.

**Results:** Nitrate partially reduced IL-6 and TNF- $\alpha$  secretion *via* reducing NF- $\kappa$ B signaling in LPS-induced macrophages. Nitrate also reduced the generation of mitochondrial reactive oxygen species by regulating mitochondrial function. These effects depended on XOR-derived NO but were independent of inducible nitric oxide synthase-derived NO.

**Conclusion:** Nitrate regulates mitochondrial function *via* XOR-derived NO to partially inhibit LPS-induced inflammation.

## Corresponding authors:

Zhengxue Han and Lizheng Qin, Department of Oral and Maxillofacial & Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Tian Tan Xi Li No.4, Dong Cheng District, Beijing 100050, China.

Emails: [hanf1989@hotmail.com](mailto:hanf1989@hotmail.com); [qinlizheng@aliyun.com](mailto:qinlizheng@aliyun.com)

Department of Oral and Maxillofacial & Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative

Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

## Keywords

Nitrate, nitric oxide, lipopolysaccharide, mitochondrial reactive oxygen species, mitochondrial function, xanthine oxidoreductase

Date received: 9 September 2019; accepted: 7 January 2020

## Introduction

Nitrate is a common inorganic molecule that is widely found in green vegetables. Over the past decades, nitrate has been confirmed to have protective effects in many diseases.<sup>1–10</sup> The bioavailability of nitrate mainly depends on a unique group of bacterial nitrate reductases in the mouth and gut of mammals that reduce nitrate to nitrite.<sup>1–4</sup> The effects of nitrite have been extensively studied. For instance, nitrite can be converted into many bioactive nitrides.<sup>5–10</sup> In general, researchers have tended to elucidate the mechanisms of dietary nitrate therapy by focusing on nitrite. However, recent studies have confirmed that mammals can directly degrade nitrate *via* xanthine oxidoreductase (XOR).<sup>11–13</sup> When volunteers were given dietary nitrate therapy, the *in vivo* concentrations of both nitrate and nitrite increased significantly.<sup>3</sup> Because nitrate can be directly degraded in mammals by XOR, the *in vivo* protective mechanisms of nitrate cannot be ignored.

Inflammation is a defensive response to stimuli during an immune response. Macrophages are the primary participants in an inflammatory response.<sup>14</sup> When macrophages are stimulated, such as by lipopolysaccharide (LPS), they generate superfluous reactive oxygen species (ROS).<sup>15</sup> The superfluous ROS leads to decreased ROS clearance and increased ROS production, which disrupts the homeostasis of ROS production and clearance, leading to severe oxidative stress.<sup>16</sup> Oxidative stress can further aggravate inflammatory responses, causing

more serious consequences.<sup>17</sup> Preventing superfluous ROS production is key to relieving oxidative stress.

Mitochondria are a primary source of ROS.<sup>18</sup> Normally, mitochondrial ROS (mtROS) is in a state of dynamic balance between production and elimination.<sup>19</sup> It is widely believed that mitochondria can produce a large number of harmful ROS in many different pathological environments.<sup>20,21</sup> A recent hypothesis was that superfluous mtROS could, either directly or indirectly, regulate inflammatory responses.<sup>22</sup> High mtROS levels from abnormal stimuli could directly activate NF- $\kappa$ B signaling.<sup>23,24</sup> Therefore, reducing mtROS production is a potential treatment that could alleviate inflammatory responses. Many studies have found that dietary nitrate therapy can decrease the cellular generation of mtROS, relieving oxidative stress and secondary injury *via* the nitrate-nitrite-nitric oxide (NO) pathway.<sup>5–7</sup>

The nitrate-nitrite-NO pathway is considered supplemental to the classic nitric oxide synthase (NOS) pathway for NO homeostasis.<sup>11–13</sup> Originally, nitrate was considered the endpoint product of endogenous NO metabolism; however, several studies have found that nitrate can be used as a potential donor of NO under specific circumstances.<sup>25–27</sup> The beneficial effects of nitrate have been demonstrated in a variety of animal and clinical trials. The nitrate-nitrite-NO pathway could modulate mitochondrial function and nicotinamide adenine dinucleotide phosphate

(NADPH) oxidase to alleviate cardiorenal disease and ischemia-reperfusion injury.<sup>4-7</sup> However, the mechanism of nitrate, rather than being converted to nitrite, has not been adequately studied. Thus, the hypothesis of this study was that nitrate could relieve inflammatory responses *via* XOR *in vitro*.

## Materials and methods

Ethics approval was not required because no humans or animals were used in this study.

### Cell culture and treatment

Mouse RAW264.7 macrophages were purchased from the National Infrastructure of Cell Line Resource (Beijing, China). Cells were incubated in Dulbecco's Modified Eagle's Medium (DMEM; SH30022.01, Hyclone, Logan, UT, USA) with 10% Fetal Bovine Serum (FBS; No.10099, GIBCO, Carlsbad, CA, USA), 100 IU/mL penicillin, and 100 mg/mL streptomycin. The culture was maintained in a humidified atmosphere containing 5% CO<sub>2</sub> at 37°C. Cells were passaged using a sterile cell scraper. After reaching 90% confluence, the cells were gently scraped off, counted, spread onto 6- or 96-well plates, and then incubated overnight. The next day, the medium was pre-incubated with phenol-free red DMEM and various concentrations of sodium nitrate (10, 100, and 500 μM) or sodium chloride (10, 100, and 500 μM) for 2 hours. The NO scavenger carboxy-PTIO (1 mM; S1546, Beyotime, Shanghai, China), the iNOS inhibitor L-canavanine (1 mM; S0007, Beyotime), or the XOR inhibitor allopurinol (100 μM; A8003, Sigma-Aldrich, Saint Louis, MO, USA) were added 30 minutes before the LPS incubation. Finally, LPS (10 ng/mL, from *E. coli* O111:B4, Invivogen, San Diego, CA, USA) was added to the medium at various times

to collect different samples or to measure different indicators.

### Measuring interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ) levels

IL-6 and TNF- $\alpha$  were measured using Quantikine Immunoassay Kits according to the manufacturer's instructions (431304 and 430904, BioLegend, San Diego, CA, USA). Cells were counted and spread onto a 6-well plate at a concentration of  $5 \times 10^5$  cells/mL. After pre-incubation, LPS was added to stimulate the samples for 2 hours. The medium was collected and centrifuged for 10 minutes at 1000  $\times g$ , and then the supernatant was removed to measure the concentrations of IL-6 and TNF- $\alpha$ .

### Western blot analysis

The western blotting protocol was adapted from Zollbrecht et al.<sup>29</sup> Proteins extracted from cells were lysed in Radio Immunoprecipitation Assay (RIPA) buffer with 1% protease inhibitor mixture (PIC) and 1% phenylmethylsulfonyl fluoride (PMSF). The samples were separated on a 10% SDS polyacrylamide gel and transferred to polyvinylidene difluoride membranes in a semi-dry transfer apparatus (4561033, Bio-Rad, Hercules, CA, USA). The membranes were pre-incubated at room temperature in 5% dehydrated milk for 2 hours. Then each membrane was incubated with specific primary antibodies against IKK $\alpha$  (2684, Cell Signaling Technology, Danvers, MA, USA), p-IKK $\alpha$  (2694, Cell Signaling Technology), NF- $\kappa$ B (p65) (3034, Cell Signaling Technology), p-NF- $\kappa$ B (p65) (3033, Cell Signaling Technology), iNOS (13120, Cell Signaling Technology), XOR (ab109235, Abcam, Cambridge, UK), and  $\beta$ -actin (AC026, Abclone, Wuhan, China) overnight. Next, the membranes were incubated with secondary antibodies conjugated to

horseradish peroxidase (AS014, Abclone) and visualized using enhanced chemiluminescence reagents (1705062, Bio-Rad).

### **Determining cytoplasmic ROS and mtROS**

Cytoplasmic ROS and mtROS were determined according to the protocol used by Li et al.<sup>24</sup> Briefly, cells were counted and spread onto a 96-well black opaque plate at a concentration of  $1 \times 10^5$  cells/mL. After a 2-hour LPS challenge, the cells were incubated for 10 minutes with 5 mM MitoSOX Red (M36008, Invitrogen, Carlsbad, CA, USA) to determine mtROS. The cytoplasmic ROS content of the cells was determined by incubating them for 20 minutes with 10 mM DCFH-DA (D6470, Solarbio, Beijing, China). Next, the cells were washed twice with PBS, and fluorescence intensities were measured at 510/590 nm or 488/528 nm excitation/emission wavelengths on a multi-well spectrophotometer.

### **Determining mitochondrial membrane potential ( $\Delta\Psi_m$ )**

The pre-treatment step was the same as that described for determining mtROS. The  $\Delta\Psi_m$  were determined according to the protocol developed by Prathapan et al.<sup>28</sup> Briefly, the same volume of JC-1 (C2006, Beyotime) was added and incubated with the cells for 20 minutes. Cells were then washed twice with PBS. To measure the fluorescence intensity with a multi-well spectrophotometer, the excitation/emission wavelengths were set at 490/530 nm for the JC-1 monomer and 525/590 nm for the JC-1 aggregate.

### **Measuring the activity of mitochondrial respiratory chain complexes I and III**

These methods were adapted from Shiva et al. and Dezfulian et al.<sup>7,9</sup> Briefly, cells were collected and disrupted in a Tris-HCl (pH 7.4) buffer. The buffer was centrifuged

at  $800 \times g$  for 10 minutes at 4°C. Then, the supernatant was centrifuged at  $20,000 \times g$  for 10 minutes at 4°C. The supernatant was discarded, then the pellet was re-suspended in 0.2 mM ice-cold sodium citrate. Mitochondria were lysed by ultrasound. Protein concentrations were measured by the BCA Kit (P0011, Beyotime). The activity of complex I was determined by spectrophotometry through monitoring the oxidation of NADH at 340 nm (BC0515, Solarbio). The activity of complex III was measured by monitoring the increased rate of light absorption at 550 nm (BC3245, Solarbio).

### **Reverse transcription-PCR**

The reverse transcription-PCR determination protocol is referenced from Li et al.<sup>24</sup> Briefly, total RNA was extracted from cells using TRIzol reagent according to the manufacturer's instructions (CW0581, CWbiotech, Jiangsu, China). The RNA purity (the 260/280 nm ratio) was between 1.8 and 2.0 for all samples. The RNA concentrations were approximately 300 nM. Next, cDNA was synthesized using a Prime Script RT Reagent Kit (RR047A, Takara, Otsu, Japan). Gene transcripts were quantified via RT-PCR, which was performed with a SYBR Green PCR Kit (204054, Qiagen, Limburg, Germany). The sequences of related genes were searched from the primer bank. The product sizes were approximately 150 bp. The sequences for the primers used were as follows: iNOS, 5'-GGAGTGACG GCAAACATGACT-3' (forward) and 5'-TCGATGCACAACCTGGGTGAAC-3' (reverse); XOR, 5'-ATGACG AGGACAACGGTAGAT-3' (forward) and 5'-TCATACTTGGAGATCATCACGGT-3' (reverse);  $\beta$ -actin, 5'-GGCTGTATTCCCCTCCATCG-3' (forward) and 5'-CCAGTTG GTAACAATGCCATGT-3' (reverse). The PCR conditions were 15 minutes at 95°C, followed by 40 cycles of 94°C for 15 seconds, 60°C for 30 seconds and 72°C for 30 seconds.

Gene expression was determined by the  $2^{-\Delta\Delta CT}$  method.

### Determining NO production

The pre-treatment was the same as that described for determining mtROS. NO production was determined according to the protocol published by Zollbrecht et al.<sup>29</sup> Briefly, the cells were incubated for 20 minutes with 2.5  $\mu$ M diaminofluorescein-FM diacetate (DAF-FM DA; S0019, Beyotime). Next, the cells were washed twice with PBS and the fluorescence intensity was measured at 495/525 nm excitation/emission wavelengths using a multi-well spectrophotometer.

### Statistical analysis

Data are expressed as mean  $\pm$  standard error of the mean (SEM). Statistical significance was determined using one-way ANOVA (followed by the Student's t test) for multiple comparisons. Analyses and graphs were performed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). Differences were considered statistically significant if  $p < 0.05$  (\*),  $p < 0.01$  (\*\*), or  $p < 0.001$  (\*\*\*)

## Results

### Nitrate relieved LPS-induced inflammation


We found that nitrate could gradually reduce the levels of IL-6 (Figure 1a) and TNF- $\alpha$  (Figure 1b) secretion in a concentration gradient of sodium nitrate from 100 to 500  $\mu$ M after a 2-hour LPS-induction. Then the levels of total and phosphorylated IKK $\alpha$  and NF- $\kappa$ B (p65) were measured at 1 hour (Figure 1c-d). The ratio of phosphorylated protein to total protein was used to indicate the degree of NF- $\kappa$ B pathway activation. LPS significantly activated the NF- $\kappa$ B pathway, while nitrate relieved this form of activation.

### Nitrate reduced mtROS generation and enhanced mitochondrial respiration under inflammatory conditions

The MitoSOX Red probe was used to monitor mtROS generation. After a 2-hour LPS challenge, mitochondria in the LPS-only group produced about 2.4-fold higher ROS levels than the control group ( $p < 0.001$ ). The pattern of reduced mtROS generation after LPS challenge was dependent on the sodium nitrate concentration from 100 to 500  $\mu$ M (Figure 2a). In contrast, changing the sodium chloride concentration did not affect mtROS levels following LPS challenge (Figure 2b). These data suggest that increasing nitrate, rather than sodium, concentrations led to reduced levels of mtROS. Cytoplasmic ROS content was determined by DCFHDA (Figure 2c). Sodium nitrate did not change cytoplasmic ROS production. These results suggest that sodium nitrate may regulate mtROS generation in response to oxidative stress.

The  $\Delta\Psi_m$  was determined by the fluorescence intensity of JC-1 (Figure 2d). Pictures of the red fluorescent JC-1 aggregate and the green fluorescent JC-1 monomer were taken by fluorescence microscopy. ImageJ software was used to mix the channels.  $\Delta\Psi_m$  was evaluated by the fluorescence intensity ratio of red to green (Figure 2e). Nitrate restored the decreased  $\Delta\Psi_m$ , or in some cases even exceeded the normal levels in the control group ( $p < 0.001$ ).

To determine how nitrate reduces mtROS generation and enhances  $\Delta\Psi_m$ , mitochondrial respiratory function was determined by measuring the activity of mitochondrial respiratory chain complex I (Figure 2f) and III (Figure 2g). Nitrate significantly enhanced the activity of complex I ( $p < 0.01$ ). Additionally, nitrate further inhibited the activity of complex III more than in the LPS-challenged condition. It appeared that nitrate improved mitochondrial respiratory



**Figure 1.** Nitrate relieved LPS-induced inflammation. The concentration of IL-6 (a) and TNF- $\alpha$  (b) in the supernatant after 2-hour LPS treatment ( $n = 4$ ). Western blot of total and phosphorylated levels of IKK $\alpha$  (c) and NF- $\kappa$ B (p65) (d) after 1-hour LPS treatment ( $n = 3$ ). Data are expressed as mean  $\pm$  SEM;  $p < 0.05$  (\*),  $p < 0.01$  (\*\*), and  $p < 0.001$  (\*\*\*)


capacity by activating complex I activity and inhibiting complex III activity.

### Nitrate modulated mitochondrial function via NO but did not change iNOS or XOR expression

To determine the mechanism of how nitrate regulates mitochondrial function, the NO scavenger Carboxy-PTIO was used to detect mtROS generation and  $\Delta\Psi_m$

(Figure 3a-b). When the scavenger was applied, nitrate could not reduce mtROS production or enhance  $\Delta\Psi_m$ . These data may explain the mechanism of how these effects of nitrate depend on NO.

Additionally, we measured the expression of iNOS and XOR at the mRNA and protein levels (Figure 3c-f). The results indicated that nitrate levels did not alter the high expression of iNOS following LPS stimulation. After adding LPS, a slight




**Figure 2.** Nitrate reduced mtROS generation and enhanced mitochondrial respiration under an inflammatory environment. Mitochondrial ROS levels (a) in medium loaded with LPS and various concentrations of sodium nitrate (10, 100, and 500 μM). Mitochondrial ROS levels (b) in medium loaded with LPS and various concentrations of sodium chloride (10, 100, and 500 μM). Cytoplasmic ROS levels (c) in medium loaded with LPS and various concentrations of sodium nitrate (10, 100, and 500 μM). Fluorescence micrographs (d) of JC-1 aggregate, monomer, and the merge (scale bar: 20 μm). The fluorescence intensity ratio (e) of JC-1 aggregate to monomer (red to green). Mitochondria were collected 2 hours after LPS stimulation, and the activity of complexes I (f) and III (g) were detected after ultrasonic fragmentation (n = 3). Data are expressed as mean ± SEM (n = 4); p < 0.01 (\*\*\*) and p < 0.001 (\*\*\*).

reduction in XOR mRNA expression was observed; however, this was not observed for XOR protein. Nitrate levels did not change XOR expression.

### *The effects of nitrate were dependent on XOR but independent of iNOS*

To further explore the protective mechanism of nitrate, the NO content was monitored by



**Figure 3.** Nitrate modulated mitochondrial function *via* NO and did not alter the expression of iNOS or XOR. The mtROS (a) and  $\Delta\Psi_m$  (b) after addition of the NO scavenger Carboxy-PITIO (1 mM) ( $n = 4$ ). The mRNA expression of iNOS (c) and XOR (d) in medium loaded with LPS and various concentrations of sodium nitrate (10, 100, and 500  $\mu$ M). The protein expression of iNOS (e) and XOR (f) in medium loaded with LPS and various concentrations of sodium nitrate (10, 100, and 500  $\mu$ M). Data are expressed as mean  $\pm$  SEM ( $n = 3$ );  $p < 0.05$  (\*) and  $p < 0.001$  (\*\*\*)




loading the iNOS inhibitor L-canavanine or the XOR inhibitor allopurinol. Under the iNOS inhibitor, there was increased NO generation following the concentration gradient of sodium nitrate from 100 to 500  $\mu$ M (Figure 4a). In contrast, sodium nitrate did not change NO generation in the presence of the XOR inhibitor (Figure 4b). These data suggest that sodium nitrate might act through XOR-derived NO.

Next, mtROS generation and  $\Delta\Psi_m$  were determined in the presence of the iNOS inhibitor or XOR inhibitor (Figure 4c-d). There were a statistical differences between the nitrate with L-canavanine group and the L-canavanine only group regarding


mtROS generation and  $\Delta\Psi_m$ . However, allopurinol simultaneously and significantly blocked the effects of nitrate on both mtROS generation and  $\Delta\Psi_m$ . These results further support that the effects of nitrate depend on XOR-derived NO but are independent of iNOS-derived NO.

*Nitrate does not modulate mitochondrial function or the inflammatory response of macrophages without LPS*

The  $\Delta\Psi_m$  (Figure 5a) and production of mtROS (Figure 5b), IL-6 (Figure 5c), and TNF- $\alpha$  (Figure 5d) were determined in the supernatant to assay the influence of nitrate



**Figure 4.** The effects of nitrate were dependent on XOR but independent of iNOS. NO levels in medium loaded with LPS, various concentrations of sodium nitrate (10, 100, and 500  $\mu$ M), and the iNOS inhibitor L-canavanine (1 mM) (a) or the XOR inhibitor allopurinol (100  $\mu$ M) (b). The mtROS (c) and  $\Delta\Psi_m$  (d) after L-canavanine (1 mM) and allopurinol (100  $\mu$ M) treatment. Data are expressed as mean  $\pm$  SEM (n=3);  $p < 0.01$  (\*\*) and  $p < 0.001$  (\*\*\*).



**Figure 5.** Nitrate did not modulate mitochondrial function or the inflammatory response of macrophages without LPS. After a 2-hour treatment with various concentrations of nitrate (10, 100, and 500  $\mu$ M), the  $\Delta\Psi_m$  (a), mtROS (b), and concentrations of IL-6 (c) and TNF- $\alpha$  (d) in the supernatant were detected ( $n = 3$ ). Data are expressed as mean  $\pm$  SEM.

in the absence of LPS. After a 2-hour treatment with various nitrate concentrations (10, 100, and 500  $\mu$ M), none of these indicators changed.

## Discussion

Emerging evidence has shown that nitrate has many beneficial effects on a variety of diseases.<sup>1-10</sup> Although the bioactivity of inorganic nitrate primarily depends on oral commensal bacteria,<sup>1-4</sup> some nitrate is also reduced by mammalian enzymes.<sup>11-13</sup> However, the effects of nitrate on mammalian enzymes is unclear. This may be an important part of the mechanism of nitrate therapy. Based on these findings and the paucity of studies on the effects of nitrate *in vitro*, nitrate could partially

reduce secretion of the inflammatory factors IL-6 and TNF- $\alpha$  by reducing NF- $\kappa$ B signaling in activated macrophages. The results presented herein support this hypothesis.

NADPH oxidase and other cytoplasmic and mitochondrial proteins can generate ROS.<sup>16,17</sup> High levels of ROS from abnormal stimuli can directly activate the NF- $\kappa$ B pathway.<sup>23,24</sup> Based on the above theories, nitrate may reduce the production of superfluous ROS. The content of mtROS and cytoplasmic ROS were determined to explore the mechanism of nitrate activity. Nitrate reduced mtROS generation, but did not reduce cytoplasmic ROS generation following LPS stimulation. These data suggest that nitrate may not effect NADPH oxidase and other cytoplasmic proteins. Thus, the effect of nitrate on mitochondrial

function was the focus of the rest of this study.

Normally, mitochondria play an important role in cellular energy production.<sup>18</sup> And mtROS generation is primarily through the mitochondrial respiratory chain.<sup>20</sup> In the respiratory chain, electrons are transferred to molecular oxygen by four complexes. At the same time, complexes I (NADH dehydrogenase), III (cytochrome c reductase) and IV (cytochrome c oxidase) pump protons ( $H^+$ ) into the intermembrane space, maintaining the  $\Delta\Psi_m$ .<sup>20,21</sup> During an inflammatory response, complexes I and III are the main sources of harmful mtROS.<sup>21,22</sup> Meanwhile, the generation of harmful mtROS is accompanied by a large amount of electron leakage, which results in loss of the normal  $\Delta\Psi_m$ .<sup>30,31</sup>

In this study, LPS stimulation led to a decrease in  $\Delta\Psi_m$  and the activity of complex I. However, LPS increased the activity of complex III. Decreased complex I activity leads to decreased NADH generation, increased mitochondrial electron leakage, and further increased mtROS generation. Decreased NADH production, which increases the  $FADH_2/NADH$  ratio, will promote the Q-cycle of complex III, increasing its activity as well as the formation of mtROS.<sup>32</sup>

Moreover, this research suggested that in the pre-inflammatory state, nitrate greatly improves the activity of complex I. At the same time, the output of proton pumping was also increased, which increased  $\Delta\Psi_m$ . These two results are consistent. Higher complex I activity led to more NADH generation and a lower  $FADH_2/NADH$  ratio. The reduced  $FADH_2/NADH$  ratio restored complex III activity to normal levels. These results showed that nitrate attenuated the increased mtROS following LPS challenge. Nitrate appeared to primarily regulate mitochondrial function by increasing the activity of complex I under inflammatory circumstances.

The above experiments showed that nitrate alleviated LPS-induced inflammation by regulating mitochondrial function; however, the mechanism was still unclear. Considering that nitrate may act through the nitrate-nitrite-NO pathway,<sup>1-4</sup> the NO scavenger Carboxy-PTIO was used to block the effects of nitrate. These results confirmed that NO played a key role. When NO was removed, nitrate could not reduce mtROS generation nor enhance  $\Delta\Psi_m$ . These results suggest that nitrate may act through the nitrate-nitrite-NO pathway *via* XOR.<sup>11-13,25-27</sup>

XOR catalyzes the metabolism of xanthine into uric acid and has been found to degrade nitrate to NO in biochemical experiments.<sup>26</sup> XOR is believed to be the primary source of nitrite-derived NO in living organisms.<sup>33</sup> Recently, mammals have been found to have the ability to degrade nitrate through XOR.<sup>11-13</sup> It appears that XOR may be an important participant in the effects of nitrate on mitochondrial function. However, considering how NO homeostasis modulates both the nitrate-nitrite-NO and the nitric oxide synthase (NOS) pathways, we cannot ignore the possibility that it can also be regulated by the NOS pathway.<sup>12,13</sup>

There are three kinds of NOS: neuronal (n)NOS, endothelial (e)NOS and iNOS. In macrophages, iNOS plays a crucial role in inflammatory responses.<sup>25,34</sup> Thus, the mRNA and protein expression of iNOS and XOR were measured. Nitrate did not alter the expression of iNOS or XOR following LPS induction.

Next, iNOS or XOR inhibitors were combined with LPS to eliminate interference by iNOS or XOR on NO generation while determining the NO content of the cells. These data suggested that sodium nitrate increased NO generation *via* XOR. Mitochondrial function was tested by determining mtROS generation and  $\Delta\Psi_m$  to confirm the previous findings. The XOR

inhibitor interfered with the ability of nitrate to regulate mitochondrial function under LPS challenge. This indicated that the mitochondrial regulatory capacity of nitrate was dependent on XOR.

XOR is thought to have two subtypes, xanthine oxidase (XO) and xanthine dehydrogenase (XDH).<sup>35</sup> XOR primarily exists in the XDH form, which results from the specific transcription and translation of XDH gene. XDH cannot participate in the nitrate-nitrite-NO pathway. Under pathological conditions such as inflammation and hypoxia, XDH can be reversibly transformed into XO, which has the capability to convert nitrate and nitrite.<sup>36,37</sup> Based on the above studies, it can be inferred that although nitrate can change mitochondrial function under LPS induction, it cannot change mitochondrial function under normal conditions. The  $\Delta\Psi_m$ , mtROS, and secretion of IL-6 and TNF- $\alpha$  were measured after nitrate treatment without LPS-induction. Nitrate had no influence on the levels of these indicators. These results suggest that nitrate might only work in pathological conditions.

In conclusion, many studies on inorganic nitrate and nitrite have confirmed their beneficial roles *in vivo*.<sup>1-10</sup> Most studies have tended to use nitrite to study the mechanism of this pathway. The mechanism of nitrate through XOR *in vitro* has not been studied. This study was the first to show that nitrate could alleviate inflammation by regulating mitochondrial function in a manner dependent on XOR *in vitro*. Nitrate affects mitochondrial function and the mechanism might be similar to boron and other compounds.<sup>38</sup> The most important finding was that a nitrate concentration of 500  $\mu\text{M}$ , which is slightly above the normal physiological concentration range,<sup>39</sup> could significantly alleviate inflammation. This means that the protective mechanism of nitrate is not only through what is converted to nitrite by bacterial nitrate reductases, but also

through what is converted to NO by XOR. This study suggests that nitrate in cells may bypass nitrite through the nitrate-NO pathway. These results provide a new research direction through which to evaluate nitrate therapy. It also suggests a new pathway for understanding the mechanism of nitrate.

### Declaration of conflicting interest

The authors declare that there is no conflict of interest.

### Funding

This study was supported by the National Natural Science Foundation of China (81570991 and 81570957).

### ORCID iD

Lizheng Qin  <https://orcid.org/0000-0003-2384-7514>

### References

1. Carlstrom M and Montenegro MF. Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease. *J Intern Med* 2019; 285: 2-18.
2. Koch CD, Gladwin MT, Freeman BA, et al. Enterosalivary nitrate metabolism and the microbiome: intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. *Free Radic Biol Med* 2017; 105: 48-67.
3. Carlstrom M, Lundberg JO and Weitzberg E. Mechanisms underlying blood pressure reduction by dietary inorganic nitrate. *Acta Physiol (Oxf)* 2018; 224: e13080.
4. Waltz P, Escobar D, Botero AM, et al. Nitrate/nitrite as critical mediators to limit oxidative injury and inflammation. *Antioxid Redox Signal* 2015; 23: 328-339.
5. Ingram TE, Fraser AG, Bleasdale RA, et al. Low-dose sodium nitrite attenuates myocardial ischemia and vascular ischemia-reperfusion injury in human models. *J Am Coll Cardiol* 2013; 61: 2534-2541.

6. Liu M, Zollbrecht C, Peleli M, et al. Nitrite-mediated renal vasodilatation is increased during ischemic conditions via cGMP-independent signaling. *Free Radic Biol Med* 2015; 84: 154–160.
7. Shiva S, Sack MN, Greer JJ, et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. *J Exp Med* 2007; 204: 2089–2102.
8. Vitturi DA and Patel RP. Current perspectives and challenges in understanding the role of nitrite as an integral player in nitric oxide biology and therapy. *Free Radic Biol Med* 2011; 51: 805–812.
9. Dezfulian C, Shiva S, Alekseyenko A, et al. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. *Circulation* 2009; 120: 897–905.
10. Jin L, Qin L, Xia D, et al. Active secretion and protective effect of salivary nitrate against stress in human volunteers and rats. *Free Radic Biol Med* 2013; 57: 61–67.
11. Huang L, Borniquel S and Lundberg JO. Enhanced xanthine oxidoreductase expression and tissue nitrate reduction in germ free mice. *Nitric Oxide* 2010; 22: 191–195.
12. Carlstrom M, Liu M, Yang T, et al. Crosstalk between nitrate-nitrite-NO and NO synthase pathways in control of vascular NO homeostasis. *Antioxid Redox Signal* 2015; 23: 295–306.
13. Peleli M, Zollbrecht C, Montenegro MF, et al. Enhanced XOR activity in eNOS-deficient mice: effects on the nitrate-nitrite-NO pathway and ROS homeostasis. *Free Radic Biol Med* 2016; 99: 472–484.
14. Kabat AM and Pearce EJ. Inflammation by way of macrophage metabolism. *Science* 2017; 356: 488–489.
15. Hamidzadeh K, Christensen SM, Dalby E, et al. Macrophages and the recovery from acute and chronic inflammation. *Annu Rev Physiol* 2017; 79: 567–592.
16. Zhang L, Wang X, Cueto R, et al. Biochemical basis and metabolic interplay of redox regulation. *Redox Biol* 2019; 26: 101284.
17. Umeno A, Biju V and Yoshida Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer's disease, Parkinson's disease, and diabetes. *Free Radic Res* 2017; 51: 413–427.
18. Henze K and Martin W. Evolutionary biology: essence of mitochondria. *Nature* 2003; 426: 127–128.
19. Handy DE and Loscalzo J. Redox regulation of mitochondrial function. *Antioxid Redox Signal* 2012; 16: 1323–1367.
20. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J* 2009; 417: 1–13.
21. Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. *Free Radic Biol Med* 2016; 100: 14–31.
22. Banoth B and Cassel SL. Mitochondria in innate immune signaling. *Transl Res* 2018; 202: 52–68.
23. West AP, Brodsky IE, Rahner C, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. *Nature* 2011; 472: 476–480.
24. Li X, Wang X, Zheng M, et al. Mitochondrial reactive oxygen species mediate the lipopolysaccharide-induced pro-inflammatory response in human gingival fibroblasts. *Exp Cell Res* 2016; 347: 212–221.
25. Lundberg JO, Weitzberg E, Lundberg JM, et al. Intra-gastric nitric oxide production in humans: measurements in expelled air. *Gut* 1994; 35: 1543–1546.
26. Millar TM, Stevens CR, Benjamin N, et al. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. *FEBS Lett* 1998; 427: 225–228.
27. Carlsson S, Wiklund NP, Engstrand L, et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. *Nitric Oxide* 2001; 5: 580–586.
28. Prathapan A, Vineetha VP and Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. *PLoS One* 2014; 9: e96220.

29. Zollbrecht C, Persson AE, Lundberg JO, et al. Nitrite-mediated reduction of macrophage NADPH oxidase activity is dependent on xanthine oxidoreductase-derived nitric oxide but independent of S-nitrosation. *Redox Biol* 2016; 10: 119–127.
30. Rigoulet M, Yoboue ED and Devin A. Mitochondrial ROS generation and its regulation: mechanisms involved in H<sub>2</sub>O<sub>2</sub> signaling. *Antioxid Redox Signal* 2011; 14: 459–468.
31. Szczepanek K, Chen Q, Larner AC, et al. Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. *Mitochondrion* 2012; 12: 180–189.
32. Speijer D. Can All Major ROS Forming Sites of the Respiratory Chain Be Activated By High FADH<sub>2</sub>/NADH Ratios?: ancient evolutionary constraints determine mitochondrial ROS formation. *Bioessays* 2019; 41: e1800180.
33. Cantu-Medellin N and Kelley EE. Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how. *Nitric Oxide* 2013; 34: 19–26.
34. Lowenstein CJ and Padalko E. iNOS (NOS2) at a glance. *J Cell Sci* 2004; 117: 2865–2867.
35. Asai R, Nishino T, Matsumura T, et al. Two mutations convert mammalian xanthine oxidoreductase to highly superoxide-productive xanthine oxidase. *J Biochem* 2007; 141: 525–534.
36. Nishino T, Okamoto K, Eger BT, et al. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. *FEBS J* 2008; 275: 3278–3289.
37. Kelley EE. A new paradigm for XOR-catalyzed reactive species generation in the endothelium. *Pharmacol Rep* 2015; 67: 669–674.
38. Routray I and Ali S. Boron induces lymphocyte proliferation and modulates the priming effects of lipopolysaccharide on macrophages. *PLoS One* 2016; 11: e0150607.
39. Montenegro MF, Sundqvist ML, Nihlen C, et al. Profound differences between humans and rodents in the ability to concentrate salivary nitrate: implications for translational research. *Redox Biol* 2016; 10: 206–210.